Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTC:AAWH NASDAQ:IVA NASDAQ:RAPP NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAWHAscend Wellness$0.67-2.9%$0.55$0.26▼$1.02$136.98M1.17165,148 shs72,026 shsIVAInventiva$5.61-2.8%$4.15$1.53▼$6.50$551.97M0.6971,042 shs128,196 shsRAPPRapport Therapeutics$23.76+2.4%$16.09$6.43▼$42.27$846.75M0.731.37 million shs1.67 million shsZVRAZevra Therapeutics$7.75-2.5%$10.44$6.19▼$13.16$446.27M1.561.27 million shs1.81 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAWHAscend Wellness-1.46%+1.44%+9.61%+133.43%-29.61%IVAInventiva+4.34%+3.04%+57.22%+69.21%+157.59%RAPPRapport Therapeutics+3.57%+51.14%+49.29%+107.33%+22.69%ZVRAZevra Therapeutics-0.38%-10.97%-32.40%-12.92%+7.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAWHAscend Wellness$0.67-2.9%$0.55$0.26▼$1.02$136.98M1.17165,148 shs72,026 shsIVAInventiva$5.61-2.8%$4.15$1.53▼$6.50$551.97M0.6971,042 shs128,196 shsRAPPRapport Therapeutics$23.76+2.4%$16.09$6.43▼$42.27$846.75M0.731.37 million shs1.67 million shsZVRAZevra Therapeutics$7.75-2.5%$10.44$6.19▼$13.16$446.27M1.561.27 million shs1.81 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAWHAscend Wellness-1.46%+1.44%+9.61%+133.43%-29.61%IVAInventiva+4.34%+3.04%+57.22%+69.21%+157.59%RAPPRapport Therapeutics+3.57%+51.14%+49.29%+107.33%+22.69%ZVRAZevra Therapeutics-0.38%-10.97%-32.40%-12.92%+7.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAWHAscend Wellness 1.00SellN/AN/AIVAInventiva 2.83Moderate Buy$14.83164.41% UpsideRAPPRapport Therapeutics 3.00Buy$31.0030.47% UpsideZVRAZevra Therapeutics 2.89Moderate Buy$23.71205.99% UpsideCurrent Analyst Ratings BreakdownLatest AAWH, IVA, RAPP, and ZVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025RAPPRapport TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $34.009/3/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.009/2/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $13.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/18/2025ZVRAZevra TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/13/2025ZVRAZevra TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$19.00 ➝ $18.008/12/2025AAWHAscend WellnessZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell8/6/2025RAPPRapport TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$31.007/10/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $29.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAWHAscend Wellness$518.59M0.26$0.10 per share6.64$0.69 per share0.97IVAInventiva$9.95M53.93N/AN/A($1.21) per share-4.64RAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/AZVRAZevra Therapeutics$23.61M18.42N/AN/A$0.74 per share10.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAWHAscend Wellness-$48.21M-$0.42N/AN/AN/A-15.47%-72.18%-9.55%N/AIVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$2.50N/AN/AN/AN/A-29.99%-28.64%11/6/2025 (Estimated)ZVRAZevra Therapeutics-$105.51M-$0.21N/A38.75N/A4.33%-112.40%-37.67%11/11/2025 (Estimated)Latest AAWH, IVA, RAPP, and ZVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q2 2025IVAInventiva-$0.41N/AN/AN/AN/AN/A8/7/2025Q2 2025RAPPRapport Therapeutics-$0.87-$0.75+$0.12-$0.75N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAWHAscend WellnessN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAWHAscend Wellness2.611.470.80IVAInventivaN/A0.920.92RAPPRapport TherapeuticsN/A22.7522.75ZVRAZevra Therapeutics0.527.857.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAWHAscend Wellness17.31%IVAInventiva19.06%RAPPRapport TherapeuticsN/AZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipAAWHAscend Wellness22.38%IVAInventiva32.00%RAPPRapport Therapeutics13.57%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAWHAscend Wellness2,300204.44 million166.44 millionNot OptionableIVAInventiva10095.66 million65.05 millionNot OptionableRAPPRapport TherapeuticsN/A36.50 million31.55 millionN/AZVRAZevra Therapeutics2056.13 million54.79 millionOptionableAAWH, IVA, RAPP, and ZVRA HeadlinesRecent News About These CompaniesWoodline Partners LP Acquires 476,032 Shares of Zevra Therapeutics, Inc. $ZVRASeptember 12 at 6:40 AM | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Increase in Short InterestSeptember 9 at 2:53 AM | marketbeat.comZevra Therapeutics, Inc. $ZVRA Stock Holdings Trimmed by Adage Capital Partners GP L.L.C.September 7, 2025 | marketbeat.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $23.71 Consensus Target Price from AnalystsSeptember 6, 2025 | americanbankingnews.comZevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)September 4, 2025 | globenewswire.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 4, 2025 | marketbeat.comZevra Therapeutics, Inc. $ZVRA Shares Sold by Nantahala Capital Management LLCSeptember 3, 2025 | marketbeat.comRetirement Planning Co of New England Inc. Has $4.12 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRASeptember 2, 2025 | marketbeat.comWellington Management Group LLP Purchases New Shares in Zevra Therapeutics, Inc. $ZVRASeptember 2, 2025 | marketbeat.comVelan Capital Investment Management LP Increases Stake in Zevra Therapeutics, Inc. $ZVRAAugust 31, 2025 | marketbeat.comZevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)August 28, 2025 | globenewswire.comZevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLCAugust 26, 2025 | marketbeat.comZevra Therapeutics to Participate at Upcoming Investor Conferences in SeptemberAugust 26, 2025 | globenewswire.comZacks Research Downgrades Zevra Therapeutics (NASDAQ:ZVRA) to HoldAugust 22, 2025 | marketbeat.comZevra Therapeutics rumor highlighted in Betaville blogAugust 21, 2025 | msn.comZevra Therapeutics gains amid takeover speculationAugust 21, 2025 | msn.comZevra Therapeutics (NASDAQ:ZVRA) Director John Bode Buys 5,000 SharesAugust 21, 2025 | insidertrades.comZevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 4.4% - Should You Buy?August 17, 2025 | marketbeat.comCantor Fitzgerald Brokers Lower Earnings Estimates for ZVRAAugust 17, 2025 | marketbeat.comEquities Analysts Offer Predictions for ZVRA Q3 EarningsAugust 17, 2025 | marketbeat.comQ3 EPS Forecast for Zevra Therapeutics Increased by AnalystAugust 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025What to Watch for From D-Wave Now That Earnings Are DoneBy Nathan Reiff | September 2, 2025Dueling Insider Moves: Heavy Buying Here, Big Selling ThereBy Leo Miller | September 2, 2025Is Qualcomm Tesla’s Next Rival in Autonomous Driving?By Sam Quirke | September 9, 2025AAWH, IVA, RAPP, and ZVRA Company DescriptionsAscend Wellness OTC:AAWH$0.67 -0.02 (-2.87%) As of 03:58 PM EasternAscend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.Inventiva NASDAQ:IVA$5.60 -0.17 (-2.86%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Rapport Therapeutics NASDAQ:RAPP$23.76 +0.56 (+2.41%) Closing price 04:00 PM EasternExtended Trading$23.69 -0.07 (-0.29%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Zevra Therapeutics NASDAQ:ZVRA$7.75 -0.20 (-2.52%) Closing price 04:00 PM EasternExtended Trading$7.99 +0.24 (+3.10%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
